Major Announcements - Zhaoyi Innovation plans to use 500 million CNY of A-share fundraising to increase capital in its wholly-owned subsidiaries for the implementation of the DRAM project [1] - Haiguang Information's mid-2025 profit distribution plan includes a cash dividend of 0.09 CNY per share, totaling 209 million CNY [2] - *ST Biology has terminated the major asset restructuring plan to acquire 51% of Hunan Huize Biomedical Technology Co., Ltd. [3] - Fosun Pharma intends to spin off its subsidiary Fosun Antigen for independent listing on the Hong Kong Stock Exchange [4] - Jingchen Co. has set the inquiry transfer price at 82.85 CNY per share for the transfer of 13.1 million shares [5] Performance Forecasts - Zhaoyi Innovation expects a net profit of approximately 1.61 billion CNY for 2025, a year-on-year increase of about 46% [9] - Longying Precision anticipates a net profit decrease of 17.70% to 29.36% for 2025, estimating between 545 million CNY and 635 million CNY [9] - Ruichuang Micro-Nano forecasts a net profit of around 1.1 billion CNY for 2025, representing a 93% increase [10] - Nanjing Bank projects a net profit of 21.81 billion CNY for 2025, an 8.08% increase year-on-year [11] - Zhongyuan Co. expects a net profit increase of 80% to 105% for 2025, estimating between 139 million CNY and 158 million CNY [12] - Qiangyi Co. anticipates a net profit increase of 57.87% to 71.17% for 2025, estimating between 368 million CNY and 399 million CNY [13] - Liard expects a net profit of 300 million CNY to 380 million CNY for 2025, turning from a loss of 889 million CNY in the previous year [14] - Daheng Technology forecasts a net profit of approximately 106 million CNY for 2025, also turning from a loss [16] - Dongfeng Co. anticipates a net loss of 390 million CNY to 480 million CNY for 2025 [17] - Qing Song Co. expects a net profit increase of 137.73% to 201.74% for 2025, estimating between 130 million CNY and 165 million CNY [18] - SIRUI Co. forecasts a net profit of 165 million CNY to 184 million CNY for 2025, turning from a loss [19] - Shengmei Shanghai expects a revenue increase of 18.91% to 22.47% for 2025, estimating between 6.68 billion CNY and 6.88 billion CNY [20] - Yijun Co. anticipates a net loss of 11 million CNY to 14 million CNY for 2025 [21] - Saint Yuan Environmental Protection expects a net profit increase of 31.79% to 59.24% for 2025, estimating between 240 million CNY and 290 million CNY [22] - Lijun Co. forecasts a net profit decrease of 45.05% to 60.03% for 2025, estimating between 4.8 million CNY and 6.6 million CNY [23] - Xingqi Eye Medicine expects a net profit increase of 95.82% to 121.56% for 2025, estimating between 662 million CNY and 749 million CNY [25] - Beidou Star expects a net loss of 230 million CNY to 290 million CNY for 2025, reducing losses compared to the previous year [26] - Yiling Pharmaceutical anticipates a net profit of 1.2 billion CNY to 1.3 billion CNY for 2025, turning from a loss of 725 million CNY [27] - Zhijiang Bio forecasts a net loss of 32 million CNY to 47 million CNY for 2025, reducing losses compared to the previous year [28] - Yema Battery expects a net profit decrease of 58% to 70% for 2025, estimating between 45.83 million CNY and 64.17 million CNY [29] - Yunmei Energy anticipates a net loss of 410 million CNY to 470 million CNY for 2025 [30] - Yingfang Micro expects a net loss of 69 million CNY to 97 million CNY for 2025 [31] - Guanghua Technology forecasts a net profit of 85 million CNY to 120 million CNY for 2025, turning from a loss [33] Share Buybacks - Hengyi Petrochemical plans to repurchase shares worth 500 million CNY to 1 billion CNY [34] - Yunyi Electric plans to repurchase shares worth 100 million CNY to 150 million CNY [34] - Xidun Pharmaceutical plans to repurchase shares worth 25 million CNY to 50 million CNY [35]

Core Viewpoint - The company is steadily advancing the construction of its magnesium alloy industry chain and has already established production capacity for magnesium alloy particles [1] Group 1 - The company has confirmed its production capability for magnesium alloy particles [1] - The company will fulfill its information disclosure obligations in a timely manner regarding any new developments [1]

Core Viewpoint - Lichung Group has secured multiple project designations exceeding 2 billion yuan, indicating strong market positioning and growth potential in the aluminum alloy wheel sector [1][2]. Group 1: Project Designations - Lichung Group's subsidiaries received project designations from a well-known international automotive manufacturer for aluminum alloy wheels, with an expected sales amount of approximately 1.37 billion yuan over an 8-year lifecycle starting mid-2027 [1]. - Another project designation was received for a similar aluminum alloy wheel project, with an expected sales amount of about 820 million yuan, set to begin production in July 2027 [2]. Group 2: Business Overview - Lichung Group is a leading domestic producer of aluminum alloy wheels, focusing on three main business areas: functional intermediate alloy new materials, recycled casting aluminum alloy materials, and aluminum alloy wheel products [2]. - The company has a comprehensive production capability that includes research and manufacturing of aluminum alloy materials, mold development, tooling equipment, and wheel product design [2]. Group 3: Financial Performance and Projections - The company anticipates a net profit of 830 million to 870 million yuan for the fiscal year 2025, representing a year-on-year growth of 17.38% to 23.04% [2]. - The growth in profit is attributed to a focus on core business areas, global supply chain expansion, and an increase in high-value-added products [3]. Group 4: Production and Market Strategy - The aluminum alloy wheel segment is expected to produce 23.4 million units, while the recycled casting aluminum alloy segment is projected to reach 1.26 million tons, contributing to an estimated total sales revenue of 32 billion yuan [3]. - The company is enhancing its global supply capabilities with operational bases in Thailand and Mexico, which are expected to boost sales to high-end customers [3].

Group 1 - Huakang Clean announced it is the first candidate for the bid of the Wuhan First Hospital expansion project with a bid amount of 54.88 million yuan and a construction period of 120 days [1] - Hualing Steel's subsidiary plans to invest 449.88 million yuan in a major overhaul project for its coking plant, aiming to address aging issues and restore production capacity over a 19-month construction period [2] - Yinjia Technology expects a net loss of 140 million to 110 million yuan for 2025, compared to a loss of 129 million yuan in the previous year [3] Group 2 - Guochuang High-tech forecasts a net profit of 16 million to 24 million yuan for 2025, recovering from a loss of 58.52 million yuan in the previous year [4] - Shiyi Da anticipates a net profit increase of 31 million to 46 million yuan for 2025, turning around from a loss of 23.41 million yuan last year [5] - Lijun Co. expects a net profit of 48 million to 66 million yuan for 2025, representing a decline of 45.05% to 60.03% compared to the previous year [7] Group 3 - Xindian Pharmaceutical plans to repurchase shares worth 25 million to 50 million yuan for employee stock ownership plans or equity incentives, with a maximum repurchase price of 42 yuan per share [6] - Jingchen Co. has set the initial transfer price for its shares at 82.85 yuan per share, with a total of 13.1 million shares to be transferred to 28 institutional investors [8] - Zejing Pharmaceutical received approval for clinical trials of its innovative cancer immunotherapy drug ZG005 in combination with platinum-based chemotherapy for advanced nasopharyngeal and esophageal squamous cell carcinoma [9] Group 4 - Xingqi Eye Medicine expects a net profit of 662 million to 749 million yuan for 2025, marking a growth of 95.82% to 121.56% compared to the previous year [10] - Liancheng Precision anticipates a net loss of 12 million to 17 million yuan for 2025, reducing its loss from 37.96 million yuan in the previous year [11] - Beidou Star expects a net loss of 230 million to 290 million yuan for 2025, improving from a loss of 350 million yuan last year [13] Group 5 - Qing Shan Paper's affiliate won a bid for a wastewater treatment project worth 51.9 million yuan [15] - Yiling Pharmaceutical forecasts a net profit of 1.2 billion to 1.3 billion yuan for 2025, recovering from a loss of 725 million yuan in the previous year [16] - Huahai Pharmaceutical received a drug registration certificate for its product used in treating depression and obsessive-compulsive disorder [23] Group 6 - Nanjing Panda expects a net profit of 10 million to 15 million yuan for 2025, turning around from a loss of 189 million yuan last year [40] - Rui Sheng Intelligent anticipates a net profit of 33.92 million to 38.40 million yuan for 2025, representing a growth of 112% to 140% compared to the previous year [41] - Jiechang Drive expects a net profit of 395 million to 437 million yuan for 2025, with a growth of 40% to 55% compared to the previous year [43]

人民财讯1月22日电，立中集团（300428）1月22日公告，子公司墨西哥立中和天津立中于近日收到某国 际知名汽车制造商铝合金车轮项目的定点通知。项目预计2027年中旬开始量产，项目生命周期8年，预 计项目周期内销售金额约13.7亿元。本次定点项目不排除后续其它项目共同使用产品的可能性。 ...

格隆汇1月22日丨立中集团(300428.SZ)公布，公司子公司墨西哥立中和天津立中于近日收到客户铝合金 车轮项目的定点通知。该项目预计2027年中旬开始量产，项目生命周期8年，预计项目周期内销售金额 约13.7亿元。本次定点项目不排除后续其它项目共同使用产品的可能性。 ...

立中集团（300428）(300428.SZ)公告，公司子公司Lizhong Mexico S DE RL DE CV(简称"墨西哥立中") 和天津立中车轮有限公司(简称"天津立中")于近日收到某国际知名汽车制造商铝合金车轮项目的定点通 知。项目预计2027年中旬开始量产，项目生命周期8年，预计项目周期内销售金额约13.7亿元。 ...

智通财经APP讯，立中集团(300428.SZ)公告，公司子公司Lizhong Mexico S DE RL DE CV(简称"墨西哥 立中")和天津立中车轮有限公司(简称"天津立中")于近日收到某国际知名汽车制造商铝合金车轮项目的 定点通知。项目预计2027年中旬开始量产，项目生命周期8年，预计项目周期内销售金额约13.7亿元。 ...

格隆汇1月22日｜立中集团(300428.SZ)公告称，公司子公司墨西哥立中和天津立中近日收到某国际知名 汽车制造商铝合金车轮项目的定点通知。项目预计2027年中旬开始量产，项目生命周期8年，预计项目 周期内销售金额约13.7亿元。本次定点项目不排除后续其它项目共同使用产品的可能性。客户的定点通 知是客户对公司指定铝合金车轮开发和供货资格的认可，不构成最终订单或销售合同，产品的实际供货 时间、供货价格、供货数量以正式供货协议或销售订单为准，存在不确定性影响。 ...

证券代码：300428 证券简称：立中集团 公告编号：2026-012 号 立中四通轻合金集团股份有限公司 关于获得客户项目定点的自愿性信息披露公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 重要内容提示： 一、定点通知书概况 公司子公司墨西哥立中和天津立中于近日收到客户铝合金车轮项目的定点 通知。该项目预计 2027 年中旬开始量产，项目生命周期 8 年，预计项目周期内 销售金额约 13.7 亿元。本次定点项目不排除后续其它项目共同使用产品的可能 性。 二、对上市公司的影响 1、公司以"新材料和汽车轻量化零部件全球供应商"为市场定位，深耕铝 合金及铝合金轻量化产品近 40 年，在汽车轻量化高端铝合金车轮领域积累了丰 富的技术和生产经验。本次获得客户铝合金车轮项目定点，进一步彰显了客户对 立中四通轻合金集团股份有限公司（以下简称"公司"）子公司 Lizhong Mexico S DE RL DE CV（以下简称"墨西哥立中"）和天津立中车轮有限公 司（以下简称"天津立中"）于近日收到某国际知名汽车制造商铝合金车轮 项目的定点通知（限于保密协议，无法披露客 ...